PACB is trading 5.1% down at $1.48 amid continued volatility in small-cap biotech and lingering reaction to its mixed Q1 2026 results.
- Recent coverage highlights an earnings beat on EPS but a revenue miss and lowered 2026 guidance, which have kept sentiment cautious.
- Investors continue to rotate away from risk assets due to broader market and geopolitical tensions affecting the small-cap biotech sector.